Denali Therapeutics (NASDAQ:DNLI) Announces Quarterly Earnings Results, Beats Estimates By $0.69 EPS

Denali Therapeutics (NASDAQ:DNLI) released its quarterly earnings results on Tuesday. The company reported $0.37 EPS for the quarter, topping the consensus estimate of ($0.32) by $0.69, FiscalAI reports. The company had revenue of $17.78 million for the quarter, compared to analyst estimates of $12.22 million.

Denali Therapeutics Trading Up 3.1%

DNLI stock traded up $0.59 during mid-day trading on Tuesday, reaching $19.45. 2,417,403 shares of the stock traded hands, compared to its average volume of 1,717,879. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01. Denali Therapeutics has a 52-week low of $13.75 and a 52-week high of $27.30. The company has a market cap of $3.11 billion, a P/E ratio of -6.85 and a beta of 1.02. The stock’s fifty day moving average is $20.52 and its 200-day moving average is $21.24.

Analyst Ratings Changes

Several research firms have recently weighed in on DNLI. Wall Street Zen raised shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Thursday, October 15th. JPMorgan Chase & Co. initiated coverage on shares of Denali Therapeutics in a report on Monday, July 13th. They set an “overweight” rating and a $29.00 target price on the stock. UBS Group raised their price target on shares of Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, Robert W. Baird set a $34.00 target price on Denali Therapeutics in a report on Friday, August 7th. Thirteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $35.85.

Insider Buying and Selling at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,857 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total value of $71,624.99. Following the transaction, the insider directly owned 281,763 shares of the company’s stock, valued at $7,063,798.41. This trade represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 9.70% of the stock is currently owned by company insiders.

About Denali Therapeutics

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.